益赛普治疗类风湿关节炎疗效观察及安全性分析

The observation of clinical efficacy and security analysis of etanercept in the treatment of rheumatoid arthritis

目的探讨肿瘤坏死因子α抑制剂益赛普联合甲氨蝶呤治疗活动期类风湿关节炎的临床疗效及安全性。方法将于我院就诊的64例活动期类风湿关节炎患者随机分为试验组、对照组,每组各32例,试验组采用益赛普联合甲氨蝶呤治疗,对照组单独应用甲氨蝶呤治疗。结果经12周治疗后,试验组有效率为96.9%,对照组有效率为62.5%,试验组有效率明显高于对照组(P<0.01)。两组血沉(ESR)、C反应蛋白(CRP)、类风湿因子(RF)和抗环胍氨酸抗体(抗CCP抗体)经治疗后均明显下降,试验组下降更明显(P<0.01)。两组不良反应相似。结论益赛普联合甲氨蝶呤治疗活动期类风湿关节炎能有效改善患者的临床症状和炎症指标,对活动期类风湿关节炎有较好的疗效,短期使川不良反应轻、耐受性好。

Objective To investigate the clinical efficacy and security of etanercept combined with methotrexate in the treatment of active rheumatoid arthritis. Methods 64 patients with active rheumatoid arthritis who were treated in our hospital were randomly divided into the treatment group and control group, with 32 patients in each group. In the treatment group, the patients were treated with etanercept combined with methotrexate, and in the control group, the patients were treated with methotrexate alone. Results After 12 weeks of treatment, tile effective rates were 96.9% and 62.5% in the treatment group and control group respectively. The treatment group showed better efficacy than the control group did, and there were significant differences between them （P〈0.01）. After the treatment, the erythrocyte sedimentation rate （ESR）, C-reactive protein （CRP）, rheumatoid factor （RF） and anti-cyclic citrullinated protein antibodies （anti-CCP） in the 2 groups significantly decreased, which decreased more obviously in the treatment group （P〈0.01）. The adverse reactions between the 2 groups were similar. Conclusions The clinical symptoms and inflammatory indices in the patients with active rheumatoid arthritis can be significantly improved with the treatment of etanercept combined with methotrexate. It is an effective treatment method that can be used widely in clinical work, with few adverse reactions in the short term and good tolerance.